ArticleScientific reports2024
Deep learning models for predicting the survival of patients with hepatocellular carcinoma based on a surveillance, epidemiology, and end results (SEER) database analysis.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Development and Validation of a Machine Learning Model to Prognosticate Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2026Article
- GCE: A Framework for Interpretable Nonlinear Hazard Modeling in Cardiac Sarcoma Survival Using SEER Data.Bioengineering (Basel, Switzerland) · 2026Article
- On the estimation of years of life lost in squamous cell carcinoma of the penis: limitations and future directions.World journal of urology · 2026Article
- Comparative Analysis of Deep Learning Approaches for Histopathology-Based Survival Prediction in Hepatocellular Carcinoma.Cancers · 2026Article
- Artificial intelligence in multidisciplinary tumor boards enhancing decision making and clinical outcomes in oncology.iScience · 2025Review
- Development of a hybrid 2.5D deep learning model for glioma survival prediction using T1-weighted MRI from the CGGA database.European journal of radiology open · 2025Article
- Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study.Clinical and experimental medicine · 2025Article
- An Interpretable Deep Learning Framework for Biomarker Discovery in Complex Disease Survival Outcomes.bioRxiv : the preprint server for biology · 2025Article
- Concordance-based Predictive Uncertainty (CPU)-Index: Proof-of-concept with application towards improved specificity of lung cancers on low dose screening CT.Artificial intelligence in medicine · 2025Article
- Predicting the prognosis of epithelial ovarian cancer patients based on deep learning models.Frontiers in oncology · 2025Article
- Causal predictive modeling of survival of lung and bronchus cancer patients diagnosed during 2010-2011 in Texas.PloS one · 2025Article
- Deep neural network provides personalized treatment recommendations forJournal of Cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy with poor survival and requires long-term follow-up. Hence, we collected information on patients with Primary Hepatocellular Carcinoma in the United States from the Surveillance, Epidemiology, and EndResults (SEER) database. We used this information to establish a deep learning with a multilayer neural network (the NMTLR model) for predicting the survival rate of patients with Primary Hepatocellular Carcinoma. HCC patients pathologically diagnosed between January 2011 and December 2015 in the SEER (Surveillance, Epidemiology, and End Results) database of the National Cancer Institute of the United States were selected as study subjects. We utilized two deep learning-based algorithms (DeepSurv and Neural Multi-Task Logistic Regression [NMTLR]) and a machine learning-based algorithm (Random Survival Forest [RSF]) for model training. A multivariable Cox Proportional Hazards (CoxPH) model was also constructed for comparison. The dataset was randomly divided into a training set and a test set in a 7:3 ratio. The training dataset underwent hyperparameter tuning through 1000 iterations of random search and fivefold cross-validation. Model performance was assessed using the concordance index (C-index), Brier score, and Integrated Brier Score (IBS). The accuracy of predicting 1-year, 3-year, and 5-year survival rates was evaluated using Receiver Operating Characteristic (ROC) curves, calibration plots, and Area Under the Curve (AUC). The primary outcomes were the 1-year, 3-year, and 5-year overall survival rates. Models were developed using DeepSurv, NMTLR, RSF, and Cox Proportional Hazards regression. Model differentiation was evaluated using the C-index, calibration with concordance plots, and risk stratification capability with the log-rank test. The study included 2197 HCC patients, randomly divided into a training cohort (70%, n = 1537) and a testing cohort (30%, n = 660). Clinical characteristics between the two cohorts showed no significant statistical difference (p > 0.05). The deep learning models outperformed both RSF and CoxPH models, with C-indices of 0.735 (NMTLR) and 0.731 (DeepSurv) in the test dataset. The NMTLR model demonstrated enhanced accuracy and well-calibrated survival estimates, achieving an Area Under the Curve (AUC) of 0.824 for 1-year survival predictions, 0.813 for 3-year, and 0.803 for 5-year survival rates. This model's superior calibration and discriminative ability enhance its utility for clinical prognostication in Primary Hepatocellular Carcinoma. We deployed the NMTLR model as a web application for clinical practice. The NMTLR model have potential advantages over traditional linear models in prognostic assessment and treatment recommendations. This novel analytical approach may provide reliable information on individual survival and treatment recommendations for patients with primary liver cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.